Neurocrine Biosciences, Inc. research snapshot
NBIX AI stock analysis currently reads Neurocrine Biosciences as a profitable neuroscience company with a growing INGREZZA franchise, early CRENESSITY contribution, a cash-rich balance sheet, and product, pricing, pipeline, and acquisition-integration risk. At the July 11, 2026 data cutoff, the latest available July 8 close was $176.82 and implied market capitalization was about $17.78 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$176.82
Market cap
$17.78 billion
AI score
68 / 100
Rating
Profitable neuroscience franchise with product concentration risk
Trend status
Price is above the 50-day and 200-day averages, while a high RSI raises near-term pullback risk
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Neurocrine commercializes neuroscience and endocrine medicines, led by INGREZZA for tardive dyskinesia and Huntington disease chorea, while building CRENESSITY and a clinical pipeline. | High |
| Moat | Regulatory approvals, prescriber relationships, commercial infrastructure, neuroscience development experience, and product-specific clinical evidence support the franchise, but patents and payer access remain central. | Medium-high |
| Management | CEO Kyle Gano leads a business that is funding commercial expansion, pipeline investment, buybacks, and the planned Soleno acquisition. Capital allocation should be judged by diversification and post-acquisition returns. | Medium |
| Financial trend | FY2025 revenue grew 21.5% to $2.861 billion and GAAP net income reached $478.6 million. Q1 2026 revenue grew 42% to $814.5 million, helped by $656.9 million of INGREZZA sales and $153.3 million of CRENESSITY sales. | High |
| Valuation | At the latest $176.82 close, NBIX was valued at about $17.78 billion, or 27.2x TTM EPS, 5.2x book value, and 21.4x free cash flow per share using verified inputs. | Medium-high |
| Technical trend | The latest technical reference is positive because price is above the 50-day and 200-day averages, but RSI near 73.6 indicates extended momentum rather than a low-risk entry. | Medium |
| Risk level | Risk is medium-high because INGREZZA remains the dominant revenue driver and the thesis faces pricing, reimbursement, competition, trial, regulatory, and acquisition-integration risk. | High |
| AI confidence | Reported facts and calculations are well supported, while precise price outcomes cannot be reliably predicted for a pharmaceutical company with event risk. | High data confidence |
| Investment certainty | Medium certainty. Profitability and net cash help, but durable returns require product diversification and continued execution after the current growth phase. | Medium |
NBIX AI stock forecast
The NBIX AI stock forecast uses a three-year scenario model around the $176.82 July 8 close, TTM EPS of $6.50, and verified valuation math. The output is conditional rather than a price promise: about $256 in a bullish case, $156 in a base case, and $90 in a bearish case before any possible corporate actions.
$245 to $265
More likely if INGREZZA sales remain near or above the $2.7 billion to $2.8 billion 2026 guidance range, CRENESSITY expands, the Soleno transaction adds value, late-stage pipeline programs progress, and investors sustain a premium earnings multiple.
$150 to $160
More likely if EPS compounds near 10% annually, INGREZZA growth moderates, CRENESSITY and newer products contribute gradually, R&D and commercial investment remain elevated, and the market values NBIX near an 18x earnings multiple.
$85 to $95
More likely if price or reimbursement pressure reduces INGREZZA economics, CRENESSITY adoption disappoints, pipeline studies fail, integration costs rise, or investors compress the multiple toward 13x earnings.
NBIX AI technical analysis
NBIX AI technical analysis is positive but extended at the July 11, 2026 cutoff. The latest available July 8 close was $176.82, above the 50-day moving average near $158.01 and the 200-day average near $143.10. RSI was 73.62, which supports momentum but also makes a pullback or consolidation plausible.
| Level | Value | Why it matters |
|---|---|---|
| Latest available close | $176.82 | StockAnalysis market-cap snapshot at the July 8, 2026 close. Markets were closed by the July 11 research cutoff. |
| Near support | $158 | The 50-day moving average was $158.01 in the latest StockAnalysis statistics reference. |
| Secondary support | $143 | The 200-day moving average was $143.10 in the latest StockAnalysis statistics reference. |
| Resistance | $178 to $179 | The latest 52-week high area was $178.75 in the July 7 StockAnalysis market snapshot. |
| Moving averages | $158.01 and $143.10 | The 50-day and 200-day averages were both below the latest close, consistent with a positive intermediate trend. |
| Momentum | RSI 73.62 | RSI above 70 can show strong demand and a more extended entry condition. It is not a stand-alone sell signal. |
| Volume | 20-day average 1.19 million shares | Volume confirmation matters most around earnings, product-sales updates, trial results, regulatory events, and acquisition news. |
| Volatility | Beta 0.39 with event risk | The five-year beta was 0.39, but drug-specific news can produce moves that beta does not capture. |
| Invalidation | Close below $158, then $143 | A sustained break below the 50-day average weakens the near-term trend. A break below the 200-day average should trigger a fresh chart and business review. |
NBIX AI trading strategy
The NBIX AI trading strategy is a rules-based framework for a profitable pharmaceutical company with concentrated product exposure and clinical-event risk. It is not personal advice and should be checked against live prices, filings, earnings releases, drug data, and individual risk limits.
Watch for NBIX to hold above the $158 50-day average or break and hold above the $178 to $179 high area with supportive volume and no deterioration in product-sales or clinical data.
A sustained close below $158 weakens the setup. A close below $143 should invalidate the intermediate trend framework and prompt a fundamental review.
If NBIX pulls back toward $158 or $143 without new pricing, payer, clinical, regulatory, or integration problems, compare the move with INGREZZA demand, CRENESSITY prescriptions, cash, and guidance.
Do not assume every decline is a buying opportunity. A product-specific setback, trial failure, reimbursement change, or acquisition issue can alter the business case.
Track INGREZZA sales and net price, CRENESSITY reimbursement and uptake, 2026 guidance, Soleno transaction progress, R&D milestones, operating margin, cash and marketable securities, debt, share count, and competitors.
Lower confidence if revenue concentration rises, guidance weakens, pipeline spend fails to create credible options, or the valuation stays high while earnings quality or cash conversion deteriorates.
Investment research summary
Neurocrine turns neuroscience, endocrine, and immunology research into prescription-medicine revenue by gaining approvals, building specialist demand, supporting payer access, and managing products through their life cycles.
The moat comes from approved products, clinical evidence, regulatory know-how, specialist relationships, commercial infrastructure, intellectual property, and accumulated development experience. It weakens when competitors, payers, or patent expiry change a medicine's economics.
The thesis fails if INGREZZA growth or pricing weakens faster than new products scale, CRENESSITY demand slows, trials disappoint, regulators or payers restrict access, the Soleno transaction underperforms, or R&D spending does not earn adequate returns.
Management is allocating cash toward internal research, product commercialization, repurchases, and the Soleno acquisition. The key test is whether those choices create a broader, durable earnings base rather than increasing dependence on one franchise.
Neurological and rare endocrine conditions can benefit from diagnosis, specialist care, and novel therapies, but the industry has concentrated product economics, binary clinical studies, payer scrutiny, and policy risk.
NBIX has positive earnings and net cash, but its valuation already reflects continued growth. Margin of safety improves if new products and pipeline assets diversify earnings, and narrows if INGREZZA faces faster price, access, or competitive pressure.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NBIX price | $176.82 at July 8, 2026 close | StockAnalysis market-cap snapshot | July 11, 2026 |
| Market capitalization | $17.78 billion, verified as $176.82 x 100.55 million shares | financial_rigor.py market-cap verification and StockAnalysis | July 11, 2026 |
| FY2025 revenue | $2.8605 billion, up 21.5% year over year | Neurocrine 2025 Form 10-K and StockAnalysis cross-check | July 11, 2026 |
| FY2025 GAAP net income | $478.6 million | Neurocrine 2025 Form 10-K and Macrotrends cross-check | July 11, 2026 |
| Q1 2026 revenue and GAAP net income | $814.5 million and $197.9 million, up 42% and 2,405% year over year | Neurocrine Q1 2026 financial results | July 11, 2026 |
| Q1 2026 product sales | $656.9 million INGREZZA and $153.3 million CRENESSITY | Neurocrine Q1 2026 financial results | July 11, 2026 |
| Cash and marketable securities at March 31, 2026 | $2.6472 billion, cross-validated against StockAnalysis balance-sheet data | Neurocrine Q1 2026 financial results | July 11, 2026 |
| 2026 INGREZZA sales guidance | $2.7 billion to $2.8 billion | Neurocrine Q1 2026 financial results | July 11, 2026 |
This NBIX page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecast ranges are scenarios based on available data and may be wrong if financial results, drug pricing, reimbursement, clinical evidence, regulation, competition, acquisition execution, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
